Page last updated: 2024-08-17

prednisone and selinexor

prednisone has been researched along with selinexor in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Aboukameel, A; Azmi, AS; Baloglu, E; Bhutani, D; Carlson, R; Elloul, S; Kauffman, M; Mohammad, RM; Muqbil, I; Senapedis, W; Shacham, S; Zonder, J	1
Aboukameel, A; Azmi, AS; Bhutani, D; Chaker, M; Corona, K; Houde, C; Huddlestun, A; Kauffman, M; Khan, HY; Landesman, Y; Li, Y; Mohammad, RM; Muqbil, I; Neveux, C; Pregja, S; Ramchandren, R; Reichel, K; Seymour, EK; Shacham, S; Shah, J; Sterbis, G; Yang, J; Zonder, JA	1

Trials

1 trial(s) available for prednisone and selinexor

Article	Year
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 06-15, Volume: 27, Issue:12 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Hydrazines; Lymphoma, Non-Hodgkin; Mice; Prednisone; Rituximab; Triazoles; Vincristine	2021

Article

Year

Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 06-15, Volume: 27, Issue:12

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Hydrazines; Lymphoma, Non-Hodgkin; Mice; Prednisone; Rituximab; Triazoles; Vincristine

2021

Other Studies

1 other study(ies) available for prednisone and selinexor

Article	Year
Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Cancer letters, 2016, 12-28, Volume: 383, Issue:2 Topics: Acrylamides; Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Everolimus; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Lymphoma, Non-Hodgkin; Mice, Inbred ICR; Mice, SCID; Oxadiazoles; Prednisone; Protein Kinase Inhibitors; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Time Factors; TOR Serine-Threonine Kinases; Transcription Factor RelA; Triazoles; Tumor Burden; Vincristine; Xenograft Model Antitumor Assays	2016

Article

Year

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.

Cancer letters, 2016, 12-28, Volume: 383, Issue:2

Topics: Acrylamides; Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Everolimus; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Lymphoma, Non-Hodgkin; Mice, Inbred ICR; Mice, SCID; Oxadiazoles; Prednisone; Protein Kinase Inhibitors; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Time Factors; TOR Serine-Threonine Kinases; Transcription Factor RelA; Triazoles; Tumor Burden; Vincristine; Xenograft Model Antitumor Assays

2016